Transgenic IL-2 expression in Ewing tumor cell lines after transfection with starburst dendrimers and cationic liposomes

被引:6
作者
Ackermann, B
Engel, BC
Buttlies, B
Zibert, A
Burdach, S
机构
[1] Univ Halle Wittenberg, Dept Pediat Hematol Oncol, Lab Expt Hematol & Stem Cell Transplantat, D-06097 Halle An Der Saale, Germany
[2] Univ Halle Wittenberg, Childrens Hosp, Med Ctr, D-06097 Halle An Der Saale, Germany
[3] Univ Halle Wittenberg, Bioctr, D-06097 Halle An Der Saale, Germany
[4] Univ Dusseldorf, Biomed Res Ctr BMFZ, D-4000 Dusseldorf, Germany
关键词
Ewing tumor; gene therapy; IL-2; liposomes; Starburst dendrimer;
D O I
10.1080/08880010290097332
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunotherapy with IL-2-transduced cells requires efficient methods of gene transfer. Nonviral methods have been studied intensively in recent years. This study examined whether tumor and fibroblast cell lines established from Ewing tumor patients could be efficiently transfected with the IL-2 gene. Starburst dendrimers (Superfect), a novel transfection reagent, were chosen for a transfection study and optimal conditions for gene transfer were evaluated. Three Ewing tumor cell lines and 3 fibroblast cell lines obtained from Ewing tumor patients were analyzed. The concentration of IL-2 in the supernatant of transfected cells was measured by ELISA. All three Ewing tumor cell lines transfected by Starburst dendrimers yielded higher IL-2 levels than after lipofection. In contrast to lipofection, expression of IL-2 increased with time and peaked later. In one of three tested fibroblast cell lines, transfection using Superfect yielded higher IL- 2 levels. IL-2 production was generally lower in fibroblasts as compared to Ewing tumor cell lines. Given the low toxicity of Superfect reagent and the high efficiency of transfection, this method seems to be ideal for clinical studies on the immunotherapy of Ewing tumors.
引用
收藏
页码:509 / 520
页数:12
相关论文
共 43 条
[31]   REGRESSION OF ESTABLISHED PULMONARY METASTASES AND SUBCUTANEOUS TUMOR MEDIATED BY THE SYSTEMIC ADMINISTRATION OF HIGH-DOSE RECOMBINANT INTERLEUKIN-2 [J].
ROSENBERG, SA ;
MULE, JJ ;
SPIESS, PJ ;
REICHERT, CM ;
SCHWARZ, SL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1985, 161 (05) :1169-1188
[32]   MALIGNANT PERIPHERAL NEUROECTODERMAL TUMORS OF CHILDHOOD AND ADOLESCENCE [J].
SCHMIDT, D ;
HARMS, D ;
BURDACH, S .
VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1985, 406 (03) :351-365
[33]   COMPARISON OF GENE-THERAPY WITH INTERLEUKIN-2 GENE MODIFIED FIBROBLASTS AND TUMOR-CELLS IN THE MURINE CT-26 MODEL OF COLORECTAL-CARCINOMA [J].
SHAWLER, DL ;
DORIGO, O ;
GJERSET, RA ;
ROYSTON, I ;
SOBOL, RE ;
FAKHRAI, H .
JOURNAL OF IMMUNOTHERAPY, 1995, 17 (04) :201-208
[34]   INJECTION OF COLON-CARCINOMA PATIENTS WITH AUTOLOGOUS IRRADIATED TUMOR-CELLS AND FIBROBLASTS GENETICALLY-MODIFIED TO SECRETE INTERLEUKIN-2 (IL-2) - A PHASE-I STUDY [J].
SOBOL, RE ;
ROYSTON, I ;
FAKHRAI, H ;
SHAWLER, DL ;
CARSON, C ;
DORIGO, O ;
GJERSET, R ;
GOLD, DP ;
KOZIOL, J ;
MERCOLA, D ;
VANBEVEREN, C ;
WILSON, D .
HUMAN GENE THERAPY, 1995, 6 (02) :195-204
[35]  
Stopeck AT, 1998, CANCER GENE THER, V5, P119
[36]   BIOLOGY OF NATURAL-KILLER CELLS [J].
TRINCHIERI, G .
ADVANCES IN IMMUNOLOGY, 1989, 47 :187-376
[37]  
Veelken H, 1997, INT J CANCER, V70, P269, DOI 10.1002/(SICI)1097-0215(19970127)70:3<269::AID-IJC4>3.0.CO
[38]  
2-V
[39]   EXOGENOUS EXPRESSION OF MOUSE INTERFERON-GAMMA CDNA IN MOUSE NEURO-BLASTOMA C1300 CELLS RESULTS IN REDUCED TUMORIGENICITY BY AUGMENTED ANTI-TUMOR IMMUNITY [J].
WATANABE, Y ;
KURIBAYASHI, K ;
MIYATAKE, S ;
NISHIHARA, K ;
NAKAYAMA, E ;
TANIYAMA, T ;
SAKATA, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (23) :9456-9460
[40]  
Yoshida H, 1998, CANCER GENE THER, V5, P67